Al's Comment:

This shows that the convection enhanced delivery methods have improved to the point where they can get the drug, on average,  to over 75% of the tumor, and it should only get better with more experience.  They compare this to the PRECISE trial where the drug only got to about 20% of the tumor.

Here is a link to the poster.

There is a phase 2 clinical trial going on now for this treatment, MDNA55, in patients with recurrent or progressive GBM.

Disclaimer: Medicenna Therapeutics is a sponsor of the Musella Foundation

---

Posted on: 11/22/2017

Medicenna Presents Updates on Phase 2b Clinical Trial of MDNA55 at the Annual Meeting of the Society of Neuro-Oncology

 

---

Click HERE to return to brain tumor news headlines.